scholarly journals Detection of Tear Biomarkers for Future Prostate Cancer Diagnosis

2010 ◽  
Vol 3 (1) ◽  
pp. 26-29 ◽  
Author(s):  
Yong Li
Keyword(s):  
Prostate Cancer ◽  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Clinical Proteomics ◽  
Prostate Hyperplasia ◽  
Psa Test ◽  
Diagnosis And Prognosis ◽  
Novel Biomarkers ◽  
Unique Source ◽  
Benign Prostate

Prostate cancer (CaP) continues to be the second leading cause of cancer-specific death in men in Western countries. The marker currently used for CaP detection is an increase in serum prostate specific antigen (PSA). However, the PSA test may give false positive or negative information and does not allow the differentiation of benign prostate hyperplasia (BPH), non-aggressive CaP and aggressive CaP. Tears are a unique source of body fluid and contain proteins, peptides, mucins and lipids, which is useful for studying clinical proteomics. Advances in the field of proteomics have greatly enhanced the study of tears, with a greater number of proteins now being identified in tears. Identification of novel biomarkers in tear is a new area of development. Modern advances in the field of proteomic techniques hold the promise of providing the clinical oncologists with new tools to find novel CaP biomarkers for early diagnosis and prognosis.

scholarly journals Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Chun-Jen Hsiao ◽  
Tzong-Shin Tzai ◽  
Chein-Hung Chen ◽  
Wen-Horng Yang ◽  
Chung-Hsuan Chen
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Benign Prostate Hyperplasia ◽  
Clinical Sample ◽  
Specific Antigen ◽  
Ion Accumulation ◽  
Detection Sensitivity ◽  
Prostate Hyperplasia ◽  
Liquid Chromatography Tandem Mass ◽  
Benign Prostate

Glycans of prostate-specific antigen (PSA) in prostate cancer were found to be different from that in benign disease. It is difficult to analyze heterogeneous PSA glycoforms in each individual specimen because of low protein abundance and the limitation of detection sensitivity. We developed a method for prostate cancer diagnosis based on PSA glycoforms. Specific glycoforms were screened in each clinical sample based on liquid chromatography-tandem mass spectrometry with ion accumulation. To look for potential biomarkers, normalized abundance of each glycoform in benign prostate hyperplasia (BPH) and in prostate cancer was evaluated. The PSA glycoform, Hex5HexNAc4NeuAc1dHex1, and monosialylated, sialylated, and unfucosylated glycoforms differed significantly between the prostate cancer and BPH samples. The detection sensitivity (87.5%) and specificity (60%) for prostate cancer identification are higher than those of the serum PSA marker. As low as 100 amol PSA could be detected with the ion accumulation method which has not been reported before. The improved detection specificity can help reduce unnecessary examinations.

scholarly journals Urinary PSA in monitoring of patients with prostate cancer

2012 ◽  
Vol 59 (1) ◽  
pp. 57-60 ◽  
Author(s):  
Tomislav Pejcic ◽  
V. Dimitrijevic ◽  
Jovan Hadzi-Djokic
Keyword(s):  
Prostate Cancer ◽  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Radical Retropubic Prostatectomy ◽  
Secretory Cells ◽  
Prostate Hyperplasia ◽  
Retropubic Prostatectomy ◽  
Androgen Suppression ◽  
Antiandrogen Therapy ◽  
Benign Prostate

Objective: To estimate the value of urinary prostate specific antigen (uPSA) determination in the monitoring of prostate cancer (PCa) patients. Material and methods: From January 2001 to December 2011, uPSA was determined in 397 patients. There were 265 patients with benign prostate, 19 with prostatitis and 113 with prostate cancer. Radical retropubic prostatectomy (RRP) was performed at 65 patients, while 48 patients had PCa received antiandrogen therapy. Results: Average uPSA value in the patients with benign prostate hyperplasia (BPH) was 190.8+184.2 ng/mL. Average uPSA in the patients with PCa was 287.5+303.4 ng/ml and it was not significantly different from BPH group. The average uPSA in the prostatitis group was 113.1+148.5 ng/mL, and 16.4+36.7 ng/mL in the post RRP group. During antiandrogen therapy, uPSA and PSA correlated significantly (r=0.49). Conclusion: The uPSA level reflects the response of normal prostatic and urethral secretory cells on total androgen activity. The uPSA level cannot distinguish the cases with BPH and cases with PCa. In addition, in the patients after RRP, uPSA reflects local urethral PSA production and has no role in the diagnosis of PCa recurrence. However, uPSA is better indicator of androgen suppression than testosterone (T), as it reflects the effect of suppression of all androgens, not only T.

scholarly journals Expression of Telomere Repeat Binding Factor 1 and TRF2 in Prostate Cancer and Correlation with Clinical Parameters

2017 ◽  
Vol 2017 ◽  
pp. 1-5 ◽  
Author(s):  
Wei Chen ◽  
Yong Wang ◽  
Fei Li ◽  
Wei Lin ◽  
Yong Liang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Immunohistochemical Method ◽  
Cancer Tissue ◽  
Clinical Parameters ◽  
Prostate Hyperplasia ◽  
Telomere Repeat ◽  
Binding Factor ◽  
Benign Prostate

Objective. The objective of this study was to investigate the expression of telomere repeat binding factor 1 (TRF1) and TRF2 in prostate cancer and their relationships with clinicopathological features. Methods. In total 50 prostate cancer tissues and paired benign prostate hyperplasia tissues were analyzed. The telomere-binding proteins TRF1 and TRF2 were measured using immunohistochemical method. Correlation analyses were used to evaluate the association between immunohistochemical score and clinical parameters. Results. The expression of TRF1 was significantly higher in prostate cancer tissue than in benign prostate hyperplasia tissue (χ2 = 62.69, P<0.01). Elevated levels of TRF2 were observed in both prostate cancer and benign prostate hyperplasia tissue (χ2 = 1.13, P=0.76). TRF1 expression was significantly positively correlated with surgical capsular invasion (Spearman’s r=0.43, P=0.002), seminal vesicle invasion (Spearman’s r=0.35, P=0.01), lymph nodes metastases (Spearman’s r=0.41, P=0.003), total prostate specific antigen (r=0.61, P<0.05), and Gleason score (r=0.47, P=0.01). However, there were no significant statistical differences between prostate volume (r=0.06, P=0.75) and age (r=0.14, P=0.09). Conclusion. Both TRF1 and TRF2 were overexpressed in prostate cancer. There was no specificity of TRF2 in prostate cancer, while TRF1 may be associated with prostate cancer progression.

scholarly journals Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness

Tumor Biology ◽  
2019 ◽  
Vol 41 (3) ◽  
pp. 101042831982722 ◽  
Author(s):  
Robert Lang ◽  
Vinzent Rolny ◽  
Andreas Leinenbach ◽  
Johann Karl ◽  
Magdalena Swiatek-de Lange ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Area Under The Curve ◽  
Prostate Hyperplasia ◽  
Aggressive Prostate Cancer ◽  
Total Prostate Specific Antigen ◽  
Benign Prostate ◽  
Core Fucosylation

Prostate cancer represents a major cause of cancer death in men worldwide. Novel non-invasive methods are still required for differentiation of non-aggressive from aggressive tumors. Recently, changes in prostate-specific antigen glycosylation pattern, such as core-fucosylation, have been described in prostate cancer. The objective of this study was to evaluate whether the core-fucosylation determinant of serum prostate-specific antigen may serve as refined marker for differentiation between benign prostate hyperplasia and prostate cancer or identification of aggressive prostate cancer. A previously developed liquid chromatography–mass spectrometry/mass spectrometry–based strategy was used for multiplex analysis of core-fucosylated prostate-specific antigen (fuc-PSA) and total prostate-specific antigen levels in sera from 50 benign prostate hyperplasia and 100 prostate cancer patients of different aggressiveness (Gleason scores, 5–10) covering the critical gray area (2–10 ng/mL). For identification of aggressive prostate cancer, the ratio of fuc-PSA to total prostate-specific antigen (%-fuc-PSA) yielded a 5%–8% increase in the area under the curve (0.60) compared to the currently used total prostate-specific antigen (area under the curve = 0.52) and %-free prostate-specific antigen (area under the curve = 0.55) tests. However, our data showed that aggressive prostate cancer (Gleason score > 6) and non-aggressive prostate cancer (Gleason score ≤ 6) could not significantly (p-value = 0.08) be differentiated by usage of %-fuc-PSA. In addition, both non-standardized fuc-PSA and standardized %-fuc-PSA had no diagnostic value for differentiation of benign prostate hyperplasia from prostate cancer. The %-fuc-PSA serum levels could not improve the differentiation of non-aggressive and aggressive prostate cancer compared to conventional diagnostic prostate cancer markers. Still, it is unclear whether these limitations come from the biomarker, the used patient cohort, or the imprecision of the applied method itself. Therefore, %-fuc-PSA should be further investigated, especially by more precise methods whether it could be clinically used in prostate cancer diagnosis.

scholarly journals D-dimer in the Diagnosis of Prostate Cancer

2021 ◽  
Author(s):  
Hasan Salih Sağlam ◽  
Hacı Bayram Çimen
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Benign Prostate Hyperplasia ◽  
Specific Antigen ◽  
Prostate Hyperplasia ◽  
Mri Scans ◽  
Male Patients ◽  
Magnetic Resonance Imaging Mri ◽  
Benign Prostate ◽  
D Dimer

Objective: To investigate the value of D-dimer, a marker of fibrinolysis, in metastatic and non-metastatic prostate cancer. Materials and Methods: A retrospective analysis was performed on 138 male patients including 52 patients with prostate cancer and 86 with benign prostatic hyperplasia. Participants who had factors that altered D-dimer levels were excluded. The mean ages of the groups were similar (70 ± 8 vs 68 ± 8, p= NS). In addition, data regarding biochemical findings, prostate-specific antigen and hemostatic markers, including D-dimer, were retrieved from the database of our hospital. The cut-off point of D-dimer was 0.5 mg/L. Data from scintigraphy and magnetic resonance imaging (MRI) scans related to metastasis were also considered. Patients who showed findings of metastasis according to scintigraphy and lumbosacral MRI were accepted as having metastases. Positive findings in only scintigraphy in any area were considered suspicious for metastasis. Results: Patients with prostate cancer had higher D-dimer levels than benign prostate hyperplasia patients (p= 0.024). Sixteen patients with metastatic prostate cancer and suspicious for metastasis had markedly high D-dimer levels compared to benign prostate hyperplasia and non-metastatic prostate cancer patients.

Sign in / Sign up

Export Citation Format

Share Document